Literature DB >> 10954534

CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

K L Neville1, M C Dal Canto, J A Bluestone, S D Miller.   

Abstract

Theiler's murine encephalomyelitis virus (TMEV) is a natural mouse pathogen which causes a lifelong persistent infection of the central nervous system (CNS) accompanied by T-cell-mediated myelin destruction leading to chronic, progressive hind limb paralysis. TMEV-induced demyelinating disease (TMEV-IDD) is considered to be a highly relevant animal model for the human autoimmune disease multiple sclerosis (MS), which is thought to be initiated as a secondary consequence of a virus infection. Although TMEV-IDD is initiated by virus-specific CD4(+) T cells targeting CNS-persistent virus, CD4(+) T-cell responses against self myelin protein epitopes activated via epitope spreading contribute to chronic disease pathogenesis. We thus examined the ability of antibodies directed against B7 costimulatory molecules to regulate this chronic virus-induced immunopathologic process. Contrary to previous studies showing that blockade of B7-CD28 costimulatory interactions inhibit the initiation of experimental autoimmune encephalomyelitis, treatment of SJL mice at the time of TMEV infection with murine CTLA-4 immunoglobulin or a combination of anti-B7-1 and anti-B7-2 antibodies significantly enhanced clinical disease severity. Costimulatory blockade inhibited early TMEV-specific T-cell and antibody responses critical in clearing peripheral virus infection. The inhibition of virus-specific immune responses led to significantly increased CNS viral titers resulting in increased damage to myelin-producing oligodendrocytes. Following clearance of the costimulatory antagonists, epitope spreading to myelin epitopes was accelerated as a result of the increased availability of myelin epitopes leading to a more severe chronic disease course. Our results raise concern about the potential use of B7-CD28 costimulatory blockade to treat human autoimmune diseases potentially associated with acute or persistent virus infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954534      PMCID: PMC116345          DOI: 10.1128/jvi.74.18.8349-8357.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  An early, abundant cytotoxic T-lymphocyte response against Theiler's virus is critical for preventing viral persistence.

Authors:  S Dethlefs; M Brahic; E L Larsson-Sciard
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE.

Authors:  S D Miller; C L Vanderlugt; D J Lenschow; J G Pope; N J Karandikar; M C Dal Canto; J A Bluestone
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

3.  Lack of cross-reaction between myelin basic proteins and putative demyelinating virus envelope proteins.

Authors:  N Rubio; A Cuesta
Journal:  Mol Immunol       Date:  1989-07       Impact factor: 4.407

4.  In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence.

Authors:  E L Larsson-Sciard; S Dethlefs; M Brahic
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading.

Authors:  S D Miller; C L Vanderlugt; W S Begolka; W Pao; R L Yauch; K L Neville; Y Katz-Levy; A Carrizosa; B S Kim
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

Review 6.  Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease.

Authors:  N J Karandikar; C L Vanderlugt; J A Bluestone; S D Miller
Journal:  J Neuroimmunol       Date:  1998-08-14       Impact factor: 3.478

Review 7.  The functional significance of epitope spreading and its regulation by co-stimulatory molecules.

Authors:  C L Vanderlugt; W S Begolka; K L Neville; Y Katz-Levy; L M Howard; T N Eagar; J A Bluestone; S D Miller
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

8.  Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis.

Authors:  N J Karandikar; C L Vanderlugt; T Eagar; L Tan; J A Bluestone; S D Miller
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

9.  Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. III. Failure of neuroantigen-specific immune tolerance to affect the clinical course of demyelination.

Authors:  S D Miller; S J Gerety; M K Kennedy; J D Peterson; J L Trotter; V K Tuohy; C Waltenbaugh; M C Dal Canto; H L Lipton
Journal:  J Neuroimmunol       Date:  1990-01       Impact factor: 3.478

Review 10.  Mechanisms of virus-induced demyelination and remyelination.

Authors:  M Rodriguez
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

View more
  5 in total

1.  Differential virus replication, cytokine production, and antigen-presenting function by microglia from susceptible and resistant mice infected with Theiler's virus.

Authors:  Young-Hee Jin; Mani Mohindru; Min H Kang; Alyson C Fuller; Bongsu Kang; Daniel Gallo; Byung S Kim
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

2.  CD4+CD28- costimulation-independent T cells in multiple sclerosis.

Authors:  S Markovic-Plese; I Cortese; K P Wandinger; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 3.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

4.  CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  Laurence M Howard; Katherine L Neville; Lia M Haynes; Mauro C Dal Canto; Stephen D Miller
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.

Authors:  S Marckmann; E Wiesemann; R Hilse; C Trebst; M Stangel; A Windhagen
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.